Yuki Maruyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuki Maruyama has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Motoo Araki
Department of Urology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
16 shared publications - Takuya Sadahira
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
14 shared publications - Takanori Sekito
Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
12 shared publications - Toyohiko Watanabe
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
7 shared publications - Yosuke Mitsui
Department of Urology Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
7 shared publications - Kensuke Bekku
Department of Urology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
6 shared publications
Latest Publications
- 1 April 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (4) , e70441
Editorial Comment on Survey of Herpes Zoster in Kidney Transplant Patients: A Single‐Center Study
- 1 April 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (4) , e70441
Editorial Comment on Survey of Herpes Zoster in Kidney Transplant Patients: A Single‐Center Study
- Open Access
- 28 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6102
Risk Factors for Perioperative Urinary Tract Infection After Living Donor Kidney Transplantation Characterized by High Prevalence of Desensitization Therapy: A Single-Center Analysis
Background/Objectives: Limited research exists on risk factors for urinary tract infections (UTIs) in kidney transplant recipients, particularly in high-risk groups such as ABO-incompatible or donor-specific antibody (DSA)-positive cases. Early UTIs, especially within the first month post-transplant, impact on acute rejection and long-term graft outcomes, highlighting the need for risk factor identification and management. Methods: Among 157 living donor kidney transplant cases performed at our institution between 2009 and 2024, 128 patients were included after excluding cases with >72 h of perioperative prophylactic antibiotics or urological complications. UTI was defined as the presence of pyuria and a positive urine culture, accompanied by clinical symptoms requiring antibiotic treatment, occurring within one month post-transplantation. Results: The median onset of UTI was postoperative day 8 (interquartile range, IQR: 6.8–9.3). No subsequent acute rejection episodes were observed. The median serum creatinine at 1 month postoperatively was 1.3 mg/dL (IQR: 1.1–1.7), and this was not significantly different from those who did not develop UTI. In univariate analysis, low or high BMI (25), longer dialysis duration (>2.5 years), desensitization therapy (plasmapheresis + rituximab), elevated preoperative neutrophil-to-lymphocyte ratio (NLR) (≥3), and longer warm ischemic time (WIT) (≥7.8 min) were significantly associated with an increased infection risk of UTI (p = 0.010, 0.036, 0.028, 0.015, and 0.038, respectively). Multivariate analyses revealed that abnormal BMI, longer dialysis duration, desensitization therapy, and longer WIT were independent risk factors for UTI (p = 0.012, 0.031, 0.008, and 0.033, respectively). The incidence of UTI increased with the number of risk factors: 0% (0/16) for zero, 10% (5/48) for one, 31% (16/51) for two, 45% (5/11) for three, and 100% (2/2) for four risk factors. Conclusions: Desensitization therapy, BMI, dialysis duration, and WIT were identified as independent risk factors for perioperative UTI. In patients with risk factors, additional preventive strategies should be considered, with extended antibiotic prophylaxis being one potential option.
- 28 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6102
Open AccessRisk Factors for Perioperative Urinary Tract Infection After Living Donor Kidney Transplantation Characterized by High Prevalence of Desensitization Therapy: A Single-Center Analysis
Background/Objectives: Limited research exists on risk factors for urinary tract infections (UTIs) in kidney transplant recipients, particularly in high-risk groups such as ABO-incompatible or donor-specific antibody (DSA)-positive cases. Early UTIs, especially within the first month post-transplant, impact on acute rejection and long-term graft outcomes, highlighting the need for risk factor identification and management. Methods: Among 157 living donor kidney transplant cases performed at our institution between 2009 and 2024, 128 patients were included after excluding cases with >72 h of perioperative prophylactic antibiotics or urological complications. UTI was defined as the presence of pyuria and a positive urine culture, accompanied by clinical symptoms requiring antibiotic treatment, occurring within one month post-transplantation. Results: The median onset of UTI was postoperative day 8 (interquartile range, IQR: 6.8–9.3). No subsequent acute rejection episodes were observed. The median serum creatinine at 1 month postoperatively was 1.3 mg/dL (IQR: 1.1–1.7), and this was not significantly different from those who did not develop UTI. In univariate analysis, low or high BMI (25), longer dialysis duration (>2.5 years), desensitization therapy (plasmapheresis + rituximab), elevated preoperative neutrophil-to-lymphocyte ratio (NLR) (≥3), and longer warm ischemic time (WIT) (≥7.8 min) were significantly associated with an increased infection risk of UTI (p = 0.010, 0.036, 0.028, 0.015, and 0.038, respectively). Multivariate analyses revealed that abnormal BMI, longer dialysis duration, desensitization therapy, and longer WIT were independent risk factors for UTI (p = 0.012, 0.031, 0.008, and 0.033, respectively). The incidence of UTI increased with the number of risk factors: 0% (0/16) for zero, 10% (5/48) for one, 31% (16/51) for two, 45% (5/11) for three, and 100% (2/2) for four risk factors. Conclusions: Desensitization therapy, BMI, dialysis duration, and WIT were identified as independent risk factors for perioperative UTI. In patients with risk factors, additional preventive strategies should be considered, with extended antibiotic prophylaxis being one potential option.
- Open Access
- 5 August 2025
- Published by MDPI AG in Preprints.org
Risk Factors for Perioperative Urinary Tract Infection After Living Donor Kidney Transplantation Characterized by High Prevalence of Desensitization Therapy
Background/Objectives: Limited evidence exists on risk factors for urinary tract infections (UTIs) in kidney transplant recipients, particularly in high-risk groups such as ABO-incompatible or donor-specific antibody (DSA)-positive cases. Early UTIs, especially within the first month post-transplant, impact on acute rejection and long-term graft outcomes, highlighting the need for risk factor identification and management. Methods: Among 157 living donor kidney transplant cases performed at our institution between 2009 and 2024, 128 patients were included after excluding cases with >72 hours of perioperative prophylactic antibiotics or urological complications. Desensitization therapy (plasmapheresis + rituximab) was performed in 74 cases (58%) for ABO-incompatible or DSA-positive transplantation. UTI was defined as the presence of pyuria and a positive urine culture, accompanied by clinical symptoms requiring antibiotic treatment, occurring within one month post-transplantation. Results: The median onset of UTI was postoperative day 8 (interquartile range; IQR: 6.8-9.3). No subsequent acute rejection episodes were observed. The median serum creatinine at 1 month postoperatively was 1.3 mg/dL (IQR: 1.1–1.7) and this was not significantly different from those who didn’t develop UTI. In univariate analysis, low or high BMI (25), longer dialysis duration (>2.5 years), desensitization therapy, elevated preoperative neutrophil-to-lymphocyte ratio (NLR) (≧3), and longer warm ischemic time (WIT) (≧7.8 min) were significantly associated with an increased infection risk of UTI (p = 0.010, 0.036, 0.028, 0.015, and 0.038, respectively). Multivariate analyses revealed that abnormal BMI (Odds ratio: OR = 3.35, 95% Confidence Interval; CI: 1.3-8.6, p = 0.012), longer dialysis duration (OR = 3.15, 95% CI: 1.1–9, p = 0.031), desensitization therapy (OR = 4.31, 95% CI: 1.46–12.8, p = 0.008), and longer WIT (OR = 3.53, 95% CI: 1.1–11.3, p = 0.033) were independent risk factors for UTI. The incidence of UTI increased with the number of risk factors: 0% (0/16) for zero, 10% (5/48) for one, 31% (16/51) for two, 45% (5/11) for three, and 100% (2/2) for four risk factors. Conclusions: Desensitization therapy, BMI, dialysis duration, and WIT were identified as independent risk factors for perioperative UTI. In patients with risk factors, additional preventive strategies should be considered, with extended antibiotic prophylaxis being one potential option.
- 5 August 2025
- Published by MDPI AG in Preprints.org
Open AccessRisk Factors for Perioperative Urinary Tract Infection After Living Donor Kidney Transplantation Characterized by High Prevalence of Desensitization Therapy
Background/Objectives: Limited evidence exists on risk factors for urinary tract infections (UTIs) in kidney transplant recipients, particularly in high-risk groups such as ABO-incompatible or donor-specific antibody (DSA)-positive cases. Early UTIs, especially within the first month post-transplant, impact on acute rejection and long-term graft outcomes, highlighting the need for risk factor identification and management. Methods: Among 157 living donor kidney transplant cases performed at our institution between 2009 and 2024, 128 patients were included after excluding cases with >72 hours of perioperative prophylactic antibiotics or urological complications. Desensitization therapy (plasmapheresis + rituximab) was performed in 74 cases (58%) for ABO-incompatible or DSA-positive transplantation. UTI was defined as the presence of pyuria and a positive urine culture, accompanied by clinical symptoms requiring antibiotic treatment, occurring within one month post-transplantation. Results: The median onset of UTI was postoperative day 8 (interquartile range; IQR: 6.8-9.3). No subsequent acute rejection episodes were observed. The median serum creatinine at 1 month postoperatively was 1.3 mg/dL (IQR: 1.1–1.7) and this was not significantly different from those who didn’t develop UTI. In univariate analysis, low or high BMI (25), longer dialysis duration (>2.5 years), desensitization therapy, elevated preoperative neutrophil-to-lymphocyte ratio (NLR) (≧3), and longer warm ischemic time (WIT) (≧7.8 min) were significantly associated with an increased infection risk of UTI (p = 0.010, 0.036, 0.028, 0.015, and 0.038, respectively). Multivariate analyses revealed that abnormal BMI (Odds ratio: OR = 3.35, 95% Confidence Interval; CI: 1.3-8.6, p = 0.012), longer dialysis duration (OR = 3.15, 95% CI: 1.1–9, p = 0.031), desensitization therapy (OR = 4.31, 95% CI: 1.46–12.8, p = 0.008), and longer WIT (OR = 3.53, 95% CI: 1.1–11.3, p = 0.033) were independent risk factors for UTI. The incidence of UTI increased with the number of risk factors: 0% (0/16) for zero, 10% (5/48) for one, 31% (16/51) for two, 45% (5/11) for three, and 100% (2/2) for four risk factors. Conclusions: Desensitization therapy, BMI, dialysis duration, and WIT were identified as independent risk factors for perioperative UTI. In patients with risk factors, additional preventive strategies should be considered, with extended antibiotic prophylaxis being one potential option.
- Open Access
- 6 May 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (5) , 468
Distribution of Fimbrial Genes and Their Association with Virulence and Levofloxacin Resistance/Extended-Spectrum Beta-Lactamase Production in Uropathogenic Escherichia coli
Background: Urinary tract infection (UTI) is predominantly caused by uropathogenic Escherichia coli (UPEC). Previous studies have reported that the fimbriae of UPEC are involved in virulence and antimicrobial resistance. We aimed to analyze the fimbrial gene profiles of UPEC and investigate the specificity of these expressions in symptomatic UTI, urinary device use, and levofloxacin (LVFX) resistance/extended-spectrum beta-lactamase (ESBL) production. Methods: A total of 120 UPEC strains were isolated by urine culture between 2019 and 2023 at our institution. They were subjected to an antimicrobial susceptibility test and polymerase chain reaction (PCR) to identify 14 fimbrial genes and their association with clinical outcomes or antimicrobial resistance. Results: The prevalence of the papG2 gene was significantly higher in the symptomatic UTI group by multivariate analyses (OR 5.850, 95% CI 1.390–24.70, p = 0.016). The prevalence of the c2395 gene tended to be lower in the symptomatic UTI group with urinary devices (all p < 0.05). In LVFX-resistant UPEC strains from both the asymptomatic bacteriuria (ABU) and the symptomatic UTI group, the expression of the papEF, papG3, c2395, and yadN genes tended to be lower (all p < 0.05). Conclusion: The fimbrial genes of UPEC are associated with virulence and LVFX resistance, suggesting that even UPEC with fewer motility factors may be more likely to ascend the urinary tract in the presence of the urinary devices. These findings may enhance not only the understanding of the virulence of UPEC but also the management of UTI.
- 6 May 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (5) , 468
Open AccessDistribution of Fimbrial Genes and Their Association with Virulence and Levofloxacin Resistance/Extended-Spectrum Beta-Lactamase Production in Uropathogenic Escherichia coli
Background: Urinary tract infection (UTI) is predominantly caused by uropathogenic Escherichia coli (UPEC). Previous studies have reported that the fimbriae of UPEC are involved in virulence and antimicrobial resistance. We aimed to analyze the fimbrial gene profiles of UPEC and investigate the specificity of these expressions in symptomatic UTI, urinary device use, and levofloxacin (LVFX) resistance/extended-spectrum beta-lactamase (ESBL) production. Methods: A total of 120 UPEC strains were isolated by urine culture between 2019 and 2023 at our institution. They were subjected to an antimicrobial susceptibility test and polymerase chain reaction (PCR) to identify 14 fimbrial genes and their association with clinical outcomes or antimicrobial resistance. Results: The prevalence of the papG2 gene was significantly higher in the symptomatic UTI group by multivariate analyses (OR 5.850, 95% CI 1.390–24.70, p = 0.016). The prevalence of the c2395 gene tended to be lower in the symptomatic UTI group with urinary devices (all p < 0.05). In LVFX-resistant UPEC strains from both the asymptomatic bacteriuria (ABU) and the symptomatic UTI group, the expression of the papEF, papG3, c2395, and yadN genes tended to be lower (all p < 0.05). Conclusion: The fimbrial genes of UPEC are associated with virulence and LVFX resistance, suggesting that even UPEC with fewer motility factors may be more likely to ascend the urinary tract in the presence of the urinary devices. These findings may enhance not only the understanding of the virulence of UPEC but also the management of UTI.
- 24 April 2025
- Published by Wiley in International Journal of Urology
- Vol. 32 (7) , 888-889
Editorial Comment to “The Effect of Adipose Tissue Mesenchymal Stem Cells and Melatonin in a Rat Model of Renal Ischemia Reperfusion Injury”
- 24 April 2025
- Published by Wiley in International Journal of Urology
- Vol. 32 (7) , 888-889
Editorial Comment to “The Effect of Adipose Tissue Mesenchymal Stem Cells and Melatonin in a Rat Model of Renal Ischemia Reperfusion Injury”
- 7 April 2025
- Published by Wiley in International Journal of Urology
- Vol. 32 (7) , 839-847
Impact of Early Detection and Varying Duration of Chemoprophylaxis on Venous Thromboembolism After Robot‐Assisted Radical Cystectomy
Objective: Venous thromboembolism (VTE) is one of the serious complications after robot‐assisted radical cystectomy (RARC). This study aims to investigate the optimal duration of VTE prophylaxis and the predictive value of D‐dimer measurement on the early detection of VTE.Methods: Retrospectively, we evaluated 86 RARC patients from July 2020 to September 2023. Thromboprophylaxis was modified two times (July 2020‐; no‐enoxaparin administration, June 2021‐; enoxaparin for one week postoperatively, December 2022‐; for two weeks), and patients were divided into three groups according to the duration. For early detection of VTE, D‐dimer was measured postoperatively over time. In cases of D‐dimer exceeding 10 μg/mL, contrast‐enhanced CT was performed. The incidence of VTE was analyzed, and multivariate analysis was performed to identify the predictive factors.Results: Of the 40 patients who experienced postoperative D‐dimer levels > 10 μg/mL, 37 underwent CT or ultrasound. VTE was observed in 10/26 cases (38%) in the no‐enoxaparin group, 8/36 cases (22%) in the one‐week group, and 1/24 cases (4%) in the two‐week group, with a significant difference in incidence between the no‐enoxaparin and 2‐week groups (p = 0.005). Symptomatic VTE was observed in only one case in the no‐enoxaparin group. Multivariate analyses of VTE predictive factors showed significant differences in D‐dimer levels ≥ 12 on postoperative day 1 (OR = 14.2, 95% CI 2.47–81.1, p = 0.003) and enoxaparin administration for two weeks (OR = 0.10, 95% CI 0.01–0.96, p = 0.046).Conclusion: Chemoprophylaxis for 2 weeks significantly reduces the risk of VTE after RARC. In addition, routine measurement of D‐dimer enables early detection of asymptomatic VTE, helping to prevent the development of symptomatic VTE.
- 7 April 2025
- Published by Wiley in International Journal of Urology
- Vol. 32 (7) , 839-847
Impact of Early Detection and Varying Duration of Chemoprophylaxis on Venous Thromboembolism After Robot‐Assisted Radical Cystectomy
Objective: Venous thromboembolism (VTE) is one of the serious complications after robot‐assisted radical cystectomy (RARC). This study aims to investigate the optimal duration of VTE prophylaxis and the predictive value of D‐dimer measurement on the early detection of VTE.Methods: Retrospectively, we evaluated 86 RARC patients from July 2020 to September 2023. Thromboprophylaxis was modified two times (July 2020‐; no‐enoxaparin administration, June 2021‐; enoxaparin for one week postoperatively, December 2022‐; for two weeks), and patients were divided into three groups according to the duration. For early detection of VTE, D‐dimer was measured postoperatively over time. In cases of D‐dimer exceeding 10 μg/mL, contrast‐enhanced CT was performed. The incidence of VTE was analyzed, and multivariate analysis was performed to identify the predictive factors.Results: Of the 40 patients who experienced postoperative D‐dimer levels > 10 μg/mL, 37 underwent CT or ultrasound. VTE was observed in 10/26 cases (38%) in the no‐enoxaparin group, 8/36 cases (22%) in the one‐week group, and 1/24 cases (4%) in the two‐week group, with a significant difference in incidence between the no‐enoxaparin and 2‐week groups (p = 0.005). Symptomatic VTE was observed in only one case in the no‐enoxaparin group. Multivariate analyses of VTE predictive factors showed significant differences in D‐dimer levels ≥ 12 on postoperative day 1 (OR = 14.2, 95% CI 2.47–81.1, p = 0.003) and enoxaparin administration for two weeks (OR = 0.10, 95% CI 0.01–0.96, p = 0.046).Conclusion: Chemoprophylaxis for 2 weeks significantly reduces the risk of VTE after RARC. In addition, routine measurement of D‐dimer enables early detection of asymptomatic VTE, helping to prevent the development of symptomatic VTE.
- Open Access
- 18 November 2024
- Published by Wiley in International Journal of Urology
- Vol. 32 (3) , 258-263
Postoperative infections after robotic‐assisted radical prostatectomy in a single large institution: Effect of type and duration of prophylactic antibiotic administration
Objective: We evaluated the incidence of and risk factors for postoperative infections after robotic‐assisted radical prostatectomy (RARP) according to the type and duration of prophylactic antibiotic administration. Methods: A total of 1038 patients underwent RARP at our institution from 2010 to 2021; 1026 patients (201 in the cefazolin [CEZ] group and 825 in the ampicillin/sulbactam [ABPC/SBT] group) were analyzed, and 12 who used other antibiotics were excluded. The primary endpoint was the incidence of urinary tract infection (UTI), surgical site infection (SSI), and remote infection (RI). T‐tests, propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were performed. Multivariate logistic regression analysis was performed to evaluate the effect of type and duration of prophylactic antibiotic administration. Results: The incidence of UTI was 2.5% (5/201) in the CEZ group and 3.2% (26/825) in the ABPC/SBT group, with no significant difference between groups ( p = 0.622). The rates of SSI and RI were comparable between groups ( p = 0.680 and 0.906, respectively). Although the duration of antimicrobial therapy was longer in the ABPC/SBT group ( p < 0.001), there was no significant difference in the incidence of UTI/SSI/RI after PSM and IPTW (all p > 0.05). Multivariate logistic regression analysis showed that neither the type of antibiotic nor the duration of administration affected the incidence of UTI/SSI/RI. Conclusion: The risk of postoperative UTI/SSI/RI after RARP did not change with the type and duration of antimicrobial therapy.
- 18 November 2024
- Published by Wiley in International Journal of Urology
- Vol. 32 (3) , 258-263
Open AccessPostoperative infections after robotic‐assisted radical prostatectomy in a single large institution: Effect of type and duration of prophylactic antibiotic administration
Objective: We evaluated the incidence of and risk factors for postoperative infections after robotic‐assisted radical prostatectomy (RARP) according to the type and duration of prophylactic antibiotic administration. Methods: A total of 1038 patients underwent RARP at our institution from 2010 to 2021; 1026 patients (201 in the cefazolin [CEZ] group and 825 in the ampicillin/sulbactam [ABPC/SBT] group) were analyzed, and 12 who used other antibiotics were excluded. The primary endpoint was the incidence of urinary tract infection (UTI), surgical site infection (SSI), and remote infection (RI). T‐tests, propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were performed. Multivariate logistic regression analysis was performed to evaluate the effect of type and duration of prophylactic antibiotic administration. Results: The incidence of UTI was 2.5% (5/201) in the CEZ group and 3.2% (26/825) in the ABPC/SBT group, with no significant difference between groups ( p = 0.622). The rates of SSI and RI were comparable between groups ( p = 0.680 and 0.906, respectively). Although the duration of antimicrobial therapy was longer in the ABPC/SBT group ( p < 0.001), there was no significant difference in the incidence of UTI/SSI/RI after PSM and IPTW (all p > 0.05). Multivariate logistic regression analysis showed that neither the type of antibiotic nor the duration of administration affected the incidence of UTI/SSI/RI. Conclusion: The risk of postoperative UTI/SSI/RI after RARP did not change with the type and duration of antimicrobial therapy.
- 17 April 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (4) , 102097
Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab
- 17 April 2024
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 22 (4) , 102097
Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab
- 17 February 2024
- Published by Wiley in International Journal of Urology
- Vol. 31 (6) , 599-606
Current status and future perspectives on robot‐assisted kidney autotransplantation: A literature review
This review presents the latest insights on robot‐assisted kidney autotransplantation (RAKAT). RAKAT is a minimally invasive surgical procedure and represents a promising alternative to conventional laparoscopic nephrectomy followed by open kidney transplantation for the treatment of various complex urological and vascular conditions. RAKAT can be performed either extracorporeally or intracorporeally. Additionally, a single‐port approach can be performed through one small incision without the need to reposition the patient. Of 86 patients undergoing RAKAT, 8 (9.3%) developed postoperative > Grade 2 Clavien‐Dindo (CD) complications. Although the feasibility of RAKAT was established in 2014, the long‐term efficacy and safety along with outcomes of this surgical approach are still being evaluated, and additional studies are needed. With improvements in the technology of RAKAT and as surgeons gain more experience, RAKAT should become increasingly used and further refined, thereby leading to improved surgical outcomes and improved patients' quality of life.
- 17 February 2024
- Published by Wiley in International Journal of Urology
- Vol. 31 (6) , 599-606
Current status and future perspectives on robot‐assisted kidney autotransplantation: A literature review
This review presents the latest insights on robot‐assisted kidney autotransplantation (RAKAT). RAKAT is a minimally invasive surgical procedure and represents a promising alternative to conventional laparoscopic nephrectomy followed by open kidney transplantation for the treatment of various complex urological and vascular conditions. RAKAT can be performed either extracorporeally or intracorporeally. Additionally, a single‐port approach can be performed through one small incision without the need to reposition the patient. Of 86 patients undergoing RAKAT, 8 (9.3%) developed postoperative > Grade 2 Clavien‐Dindo (CD) complications. Although the feasibility of RAKAT was established in 2014, the long‐term efficacy and safety along with outcomes of this surgical approach are still being evaluated, and additional studies are needed. With improvements in the technology of RAKAT and as surgeons gain more experience, RAKAT should become increasingly used and further refined, thereby leading to improved surgical outcomes and improved patients' quality of life.
- Open Access
- 1 January 2024
- Published by Wiley in Veterinary Medicine International
- Vol. 2024 (1) , 6505595
Circadian Rhythms Fluctuate the Treatment Effects of Intravesical Treatments on Rat Urinary Frequency Models
Objectives. It is still not clear how the intravesical instillation of drugs affects rat urinary frequency. This study aimed to examine the dynamics of intravesical treatments’ treatment effect on rat urinary frequency models by real‐time and extended monitoring using a novel continuous urination monitoring system. Methods. Nine eleven‐week‐old female Wistar rats were divided into three groups to receive intravesical instillation of 0.1% acetic acid (AA), 1.0% AA, or phosphate‐buffered saline (PBS). Thirty minutes later, these drugs were voided, and rats were moved to a continuous urination monitoring system, UM‐100. UM‐100 monitored rat urination quantitatively and continuously for 24 hours. Rats were then euthanized, and histopathologic examinations using a damage score validated the severity of bladder inflammation. We used nine additional rats to determine the treatment effect of various drugs against the urinary frequency. These rats were also treated with 1.0% AA in the same way and divided into three groups (n = 3 each) to receive intravesical instillation of lidocaine, silver nitrate (AgNO3), or dimethyl sulfoxide (DMSO), respectively. Thirty minutes later, rats were catheterized again and moved to the UM‐100, and their voiding was monitored for 24 hours. Results. Intravesical instillation of AA increased the urinary frequency and decreased the mean voided volume (VV) in a concentration‐dependent manner, with statistical significance at a concentration of 1.0% (urinary frequency; p = 0.0007, mean VV; p = 0.0032, respectively) compared with PBS. Histopathological analysis of these models demonstrated a significantly higher damage score of bladder mucosa in both 0.1% AA and 1.0% AA compared with PBS, with the severity in concordance with the clinical severity of urinary frequency (0.1% AA: p < 0.0001, 1.0% AA: p < 0.0001). Moreover, intravesical instillation of lidocaine, AgNO3, and DMSO decreased the urinary frequency. Continuous monitoring with UM‐100 also demonstrated that the treatment effect of these intravesically instilled drugs occurred only at night. Conclusions. The extended monitoring of rat urination by UM‐100 revealed a significant fluctuation in the treatment effect of intravesically instilled drugs between day and night. These findings may help establish novel therapies for urinary frequency.
- 1 January 2024
- Published by Wiley in Veterinary Medicine International
- Vol. 2024 (1) , 6505595
Open AccessCircadian Rhythms Fluctuate the Treatment Effects of Intravesical Treatments on Rat Urinary Frequency Models
Objectives. It is still not clear how the intravesical instillation of drugs affects rat urinary frequency. This study aimed to examine the dynamics of intravesical treatments’ treatment effect on rat urinary frequency models by real‐time and extended monitoring using a novel continuous urination monitoring system. Methods. Nine eleven‐week‐old female Wistar rats were divided into three groups to receive intravesical instillation of 0.1% acetic acid (AA), 1.0% AA, or phosphate‐buffered saline (PBS). Thirty minutes later, these drugs were voided, and rats were moved to a continuous urination monitoring system, UM‐100. UM‐100 monitored rat urination quantitatively and continuously for 24 hours. Rats were then euthanized, and histopathologic examinations using a damage score validated the severity of bladder inflammation. We used nine additional rats to determine the treatment effect of various drugs against the urinary frequency. These rats were also treated with 1.0% AA in the same way and divided into three groups (n = 3 each) to receive intravesical instillation of lidocaine, silver nitrate (AgNO3), or dimethyl sulfoxide (DMSO), respectively. Thirty minutes later, rats were catheterized again and moved to the UM‐100, and their voiding was monitored for 24 hours. Results. Intravesical instillation of AA increased the urinary frequency and decreased the mean voided volume (VV) in a concentration‐dependent manner, with statistical significance at a concentration of 1.0% (urinary frequency; p = 0.0007, mean VV; p = 0.0032, respectively) compared with PBS. Histopathological analysis of these models demonstrated a significantly higher damage score of bladder mucosa in both 0.1% AA and 1.0% AA compared with PBS, with the severity in concordance with the clinical severity of urinary frequency (0.1% AA: p < 0.0001, 1.0% AA: p < 0.0001). Moreover, intravesical instillation of lidocaine, AgNO3, and DMSO decreased the urinary frequency. Continuous monitoring with UM‐100 also demonstrated that the treatment effect of these intravesically instilled drugs occurred only at night. Conclusions. The extended monitoring of rat urination by UM‐100 revealed a significant fluctuation in the treatment effect of intravesically instilled drugs between day and night. These findings may help establish novel therapies for urinary frequency.